ArticleWorld journal of surgical oncology2025
Acute kidney injury predicts mortality, sarcopenia and postoperative morbidity in myxofibrosarcoma patients undergoing surgical resection.
Article in World journal of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMyxofibrosarcoma (MFS) is a rare, aggressive soft tissue sarcoma primarily affecting older adults. Despite curative-intent surgery and multimodal therapy, outcomes remain variable. Acute kidney injury (AKI) and sarcopenia are known complications in oncologic care, but their incidence and impact in MFS patients remain unclear.
objectiveTo assess the incidence and consequences of AKI in adult MFS patients undergoing curative-intent surgery, and its association with survival, CT-based sarcopenia progression, and postoperative morbidity.
methodsIn this retrospective single-center study, 49 adults with high-grade, N0M0 MFS who underwent curative-intent resection with or without multimodal therapy were included. AKI was defined as a ≥ 0.3 mg/dL increase in serum creatinine. Sarcopenia and adipose tissue loss were assessed via serial CT morphometry scans at the L3 lumbar level. Associations between AKI and clinical outcomes (survival, function, length of hospital stay, surgical site infection) were evaluated using regression and survival analyses.
resultsAKI occurred in 38.8% of patients and independently predicted decreased overall survival (HR 6.73; p = 0.0005). AKI was associated with accelerated loss of muscle tissue and visceral fat (all p < 0.001), functional decline (ECOG, p = 0.0078), longer hospitalization (p < 0.001), and increased wound infections (52.6% vs. 10.0%; p < 0.0001).
conclusionsThis is the first study to identify AKI as an independent predictor of mortality and sarcopenia in surgically treated MFS patients. CT morphometry may aid in early risk stratification, while renal monitoring offers a potential target for improving outcomes through nephroprotective strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.